clinical psychiatry · clinical
Reference snapshot
This snapshot describes the state of the editorial record, not a diagnosis or a recommendation to intervene.
Claim ledger
Support not yet mapped. These editorial statements retain their original wording; related topic sources are available separately and have not been assigned as claim-specific support.
Signal
Psychedelic-assisted therapy combines a psychoactive intervention with preparation, supervised administration, psychological support, and follow-up for selected psychiatric indications.
Boundary
Promising short-term signals in selected trials; low certainty for long-term safety, broad access, and unsupervised use.
Not established
Linked records do not establish a universal psychedelic-assisted therapy research protocol, diagnosis, or guaranteed outcome.
Mechanism map (working model)
A simplified causal map for orientation; it is not a diagnosis or a deterministic prediction.
Input or intervention
A psychoactive intervention embedded in preparation, supervised dosing, and psychological support
Biological pathway
Acute altered state, learning, emotion processing, expectancy, and therapeutic context
Measurable signal
Validated symptoms, functioning, adverse psychiatric events, consent quality, and durable follow-up
Boundary
Subjective intensity and a compelling experience do not establish universal efficacy or safety.
Research appraisal checklist
Evidence to prioritize
Indication-specific clinical trials, patient-important outcomes, active comparators, safety monitoring, and follow-up long enough to test durability. Regulatory status, contraindications, specialist oversight, and a credible stop or adverse-event pathway are part of the evidence—not optional extras.
Outcome anchor
Separate symptom or biomarker movement from improved function, quality of life, disease control, or another outcome that matters to patients.
Main uncertainty
The main uncertainty is how much the result depends on diagnosis, product, dose, supervision, selection, and delivery setting.
What would change the conclusion
Upgrade confidence only when independent studies reproduce the result and make harms, adherence, and durability visible.
Minimum diligence questions
- Are the intervention, dose or exposure, comparator, population, and measurement conditions clearly defined?
- Do the outcomes matter outside the experiment, and are missing data, adverse events, and conflicts visible?
- Can the result be reproduced independently, and does it justify the level of risk being discussed?
Application and translation pathway
Current application boundary
Psychedelic-assisted therapy remains a high-risk, indication-specific clinical research pathway combining compound, support, screening, and follow-up.
Research and applied uses
- Depression and treatment-resistant depression research
- PTSD and substance-use research
- Therapeutic framework and implementation studies
A staged map for separating an interesting mechanism from a reproducible, useful, and responsibly deployable application.
Screening
Assess diagnosis, medication, psychosis or mania vulnerability, consent, and medical risk.
Support
Specify preparation, supervised session, psychological support, and emergency planning.
Outcome
Use blinded or credible controls, validated symptoms, function, and durable follow-up.
Governance
Keep legal status, training, equity, adverse events, and post-session care explicit.
Research and clinical readout
Research status
Psychedelic-assisted therapy combines a psychoactive intervention with preparation, supervised administration, psychological support, and follow-up for selected psychiatric indications.
Signal confidence
Grade C (Promising short-term signals in selected trials; low certainty for long-term safety, broad access, and unsupervised use.)
Key question
How much of the observed benefit is attributable to the compound, therapeutic support, expectancy, selection, and setting—and for whom is risk unacceptable?
Clinical perspective
This is a high-risk clinical research domain requiring screening, trained support, emergency planning, consent, and post-session care.
Clinical uncertainty
How quickly standardized models can move from trials into routine care and how to balance access with psychiatric safety.
Community patterns
People report profound subjective experiences and seek retreats, microdosing, and informal facilitation, often without comparable clinical safeguards.
Common community failure mode
Equating intensity, catharsis, or a testimonial with durable treatment efficacy.
Where this is heading
Standardized support protocols, better controls, long-term registries, and equity-focused implementation research will determine responsible translation.
What to track next
Psychedelic-assisted therapy research combines a psychoactive intervention with preparation, supervised administration, psychological support, and follow-up for selected psychiatric indications.
Protocol and safety scaffold
Risk gate: Treat as clinician-supervised or research-only until safety, identity, dose, and monitoring are established.
Baseline first
- Define one meaningful outcome and a comparison window before changing the protocol.
- Record relevant symptoms, sleep, workload, medications, and confounders at baseline.
Implementation pattern
- Change one variable at a time and use the smallest meaningful intervention.
- Predefine review, washout, and escalation criteria before looking at results.
Monitor
- Track the target outcome alongside symptoms, function, and adherence.
- Check data quality and context before treating a change as a signal.
Pause or stop rules
- Pause for new or worsening symptoms, reduced normal function, or a meaningful safety concern.
- Pause signal: DIY dosing, underground facilitation, coercive settings, or claims of universal healing.
- Pause signal: Ignoring mania, psychosis vulnerability, medication interactions, trauma history, or post-session support.
Clinician gate
Obtain qualified clinician or specialist review before attempting any intervention beyond education or low-risk observation.
Glossary connections
Controversies to monitor
Controversies
- Blinding and expectancy in psychedelic trials.
- Underground access, coercion, contraindications, and commercialization of vulnerable people.
Core reference classes
Research classes
- Living systematic review of psychedelic and MDMA trials
- Systematic review of psilocybin therapy frameworks
Evidence timeline
Linked records are ordered by publication year. A newer record is not automatically stronger; design, population, and endpoint still determine weight.
Communication Strategies to Reduce Nocebo Effects
Patient Education and Counseling / PubMed - Scoping review
A 2026 scoping review synthesizes experimental and clinical communication strategies intended to reduce nocebo-related outcomes while preserving ethical informed consent.
View source recordEffects of Psychedelic Microdosing on Cognitive Functions
Neuroscience and Biobehavioral Reviews / PubMed - Preregistered systematic review and meta-analysis
A preregistered meta-analysis of controlled psychedelic microdosing studies found heterogeneous results, no general cognitive-enhancement effect, and a signal for reduced cognitive control that requires better standardized and expectancy-controlled research.
View source recordPsychedelics and MDMA for Mental Disorders: Living Systematic Review
PubMed / Living systematic review - Living systematic review and meta-analysis of randomized trials
A living review synthesized randomized trials of serotonergic psychedelics and MDMA for mental disorders, emphasizing indication-specific effects, low or very-low certainty in several comparisons, high risk of bias, psychological support, and limited long-term evidence.
View source recordEfficacy and Safety of Esketamine for Treatment-Resistant Depression: Individual Patient Data Meta-Analysis
BMC Medicine / PubMed - Registered systematic review and individual-patient-data meta-analysis
An individual-patient-data reanalysis of randomized trials found a statistically significant but modest average benefit for esketamine plus an antidepressant at four weeks, with increased sedation, dissociation, and adverse events and uncertainty about clinical magnitude.
View source recordLiving Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain
Agency for Healthcare Research and Quality - Living systematic review
AHRQ’s living review evaluates benefits and harms of cannabinoid and other plant-based treatments for chronic pain, separating THC:CBD ratios and product types while tracking modest, heterogeneous effects and adverse events.
View source recordTopic assessment
These questions test evidence interpretation and safety boundaries, not personal medical decisions.
1. What is the most defensible first question when evaluating Psychedelic-Assisted Therapy Research?
Show answer and explanation
What outcome, evidence, and risk boundary are defined?
A clear outcome, evidence design, and risk boundary keep an encyclopedia claim from becoming an unsafe recommendation.
2. What would make a claim about Psychedelic-Assisted Therapy Research more trustworthy?
Show answer and explanation
Replication with appropriate controls, context, and meaningful outcomes
Reproducibility and patient-important outcomes matter more than novelty, complexity, or an isolated signal.
Editorial update history
This log records what changed in the encyclopedia record and why the update matters for interpretation.
Added a cannabinoid dossier connecting THC, CBD, prescription medicines, chronic-pain evidence, anxiety research, cognitive and impairment effects, dependence, product quality, interactions, and regulatory boundaries.
Related record update: Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain
A-Z topic scaffolding, safety framing, learning paths, and linked evidence architecture established for the living encyclopedia.
Added encyclopedia coverage for breathwork, creatine cognition, intermittent hypoxia, ketogenic metabolism, mindfulness and interoception, nootropics, photobiomodulation, and psychedelic-assisted therapy, with topic-specific safety framing and current evidence links.
Related record update: Psychedelics and MDMA for Mental Disorders: Living Systematic Review
Added distinct dossiers for continuous glucose monitoring, GLP-1 and incretin therapeutics, metformin geroscience, rapamycin and mTOR, transcranial focused ultrasound, polygenic risk scores, digital phenotyping, and psychedelic microdosing, with evidence lanes and explicit medical and governance boundaries.
Related record update: Effects of Psychedelic Microdosing on Cognitive Functions
Added dossiers for ketamine and esketamine, sleep apnea, cuffless blood pressure, extracellular vesicles, exercise mimetics, postbiotics, nutritional psychiatry, and plasma-exchange rejuvenation claims, with clinical boundaries, community-risk framing, and current research links.
Related record update: Efficacy and Safety of Esketamine for Treatment-Resistant Depression: Individual Patient Data Meta-Analysis
Added indication-specific testosterone and male-fertility coverage alongside N-of-1 trial design and placebo, expectancy, and nocebo literacy, with explicit clinical gates and causal-inference boundaries.
Related record update: Communication Strategies to Reduce Nocebo Effects
Linked evidence records
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain
Agency for Healthcare Research and Quality • Living systematic review • Published: 2024 • Checked: Aug 17, 2026
AHRQ’s living review evaluates benefits and harms of cannabinoid and other plant-based treatments for chronic pain, separating THC:CBD ratios and product types while tracking modest, heterogeneous effects and adverse events.
How to interpret this record
What it supports
AHRQ’s living review provides a structured evidence and harms assessment for cannabinoid products used for chronic pain, including product-type and THC:CBD distinctions.
Major limitations
Effects are generally modest or heterogeneous, studies differ in formulation and route, and pain relief does not automatically mean functional recovery or low risk.
What it does not establish
The review does not establish cannabis as a universal analgesic, opioid replacement, recovery aid, or treatment for every chronic-pain condition.
Communication Strategies to Reduce Nocebo Effects
Patient Education and Counseling / PubMed • Scoping review • Published: 2026 • Checked: Aug 17, 2026
A 2026 scoping review synthesizes experimental and clinical communication strategies intended to reduce nocebo-related outcomes while preserving ethical informed consent.
How to interpret this record
What it supports
Expectation education, balanced framing, empathy, and related communication strategies may reduce some nocebo-related outcomes while preserving consent.
Major limitations
Effects vary by context, outcome, and communication design; nondisclosure can create ethical problems.
What it does not establish
Reducing nocebo burden does not justify hiding material risks, using deception, or dismissing persistent symptoms.
Psychedelics and MDMA for Mental Disorders: Living Systematic Review
PubMed / Living systematic review • Living systematic review and meta-analysis of randomized trials • Published: 2025 • Checked: Aug 17, 2026
A living review synthesized randomized trials of serotonergic psychedelics and MDMA for mental disorders, emphasizing indication-specific effects, low or very-low certainty in several comparisons, high risk of bias, psychological support, and limited long-term evidence.
How to interpret this record
What it supports
A living synthesis of randomized trials helps track indication-specific efficacy, psychological support, control conditions, adverse events, and certainty in psychedelic and MDMA research.
Major limitations
Many trials have high risk of bias, small samples, variable support, difficult blinding, and limited long-term follow-up; legal and clinical access also differ by jurisdiction.
What it does not establish
The review does not establish unsupervised use, microdosing, retreats, or self-treatment as safe or effective psychiatric care.
Effects of Psychedelic Microdosing on Cognitive Functions
Neuroscience and Biobehavioral Reviews / PubMed • Preregistered systematic review and meta-analysis • Published: 2026 • Checked: Aug 17, 2026
A preregistered meta-analysis of controlled psychedelic microdosing studies found heterogeneous results, no general cognitive-enhancement effect, and a signal for reduced cognitive control that requires better standardized and expectancy-controlled research.
How to interpret this record
What it supports
The meta-analysis synthesizes controlled microdosing studies and tests whether cognitive effects generalize across domains, substances, doses, and timing.
Major limitations
The evidence is heterogeneous, samples are limited, blinding is difficult, and acute effects may not represent durable change or clinical benefit.
What it does not establish
The analysis does not establish microdosing as cognitive enhancement, depression treatment, or safe unsupervised practice.
Efficacy and Safety of Esketamine for Treatment-Resistant Depression: Individual Patient Data Meta-Analysis
BMC Medicine / PubMed • Registered systematic review and individual-patient-data meta-analysis • Published: 2025 • Checked: Aug 17, 2026
An individual-patient-data reanalysis of randomized trials found a statistically significant but modest average benefit for esketamine plus an antidepressant at four weeks, with increased sedation, dissociation, and adverse events and uncertainty about clinical magnitude.
How to interpret this record
What it supports
Individual-patient-data reanalysis provides an indication-specific estimate of esketamine efficacy, relapse, and adverse events in randomized trials for treatment-resistant depression.
Major limitations
The average benefit was modest, some analyses had unblinding or selection concerns, and the results depend on supervised formulation, co-treatment, and follow-up.
What it does not establish
The review does not establish take-home ketamine, wellness use, universal remission, or a safe self-directed schedule.